Drug Information Update- FDA approved new drug for moderate-to-severe plaque psoriasis

The Division of Drug Information (DDI)- serving the public by providing information on human drug products and drug product regulation by FDA.

The U.S. Food and Drug Administration approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. 

Psoriasis is a skin condition that causes patches of skin redness and flaking. Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales.

Because Taltz is a medicine that affects the immune system, it is being approved with a Medication Guide to inform patients that they may have a greater risk of an infection, or an allergic or autoimmune condition. Serious allergic reactions and development or worsening of inflammatory bowel disease have been reported with the use of Taltz. Monitor patients closely for these conditions. The most common side effects include upper respiratory infections, injection site reactions and fungal (tinea) infections.

For more information, please visit: Taltz